How will the evaluation of cffDNA change the approach to prenatal screening for genetic disorders beyond the common aneuploidies in the future? Does this approach deserve widespread application across multiple risk groups, and if so, why?

How will the evaluation of cffDNA change the approach to prenatal screening for genetic disorders beyond the common aneuploidies in the future? Does this approach deserve widespread application across multiple risk groups, and if so, why?

How will the evaluation of cffDNA change the approach to prenatal screening for genetic disorders beyond the common aneuploidies in the future? Does this approach deserve widespread application across multiple risk groups, and if so, why?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Ahmed M. Al-Malt, MD

Ahmed M. Al-Malt, MD

Maternal and Fetal Medicine
Obstetrics and Gynecology
Assistant Professor
University of Central Florida College of Medicine
Orlando, FL